


## Curriculum Vitae

### **Subhash Chand, Ph.D.**

Email: schand@nib.gov.in, subhash.b08@gmail.com

Mobile: +919971552515



### **Academic Qualifications:**

1. Ph.D. (Biotechnology), Amity University, NOIDA, India.
2. M.Sc. (Microbiology), Himachal Pradesh University, Shimla, India.
3. PGDBA, Symbiosis, Symbiosis International University, Pune, India.

### **Professional Experience (in Brief)**

- **Overall Experience:** > 15 years
- **Research Projects:** Extramural: 01 (ICMR) (Co-PI) (Ongoing), Intramural: 02 (Ongoing) & 03 (Completed)
- **Research Publications:** 33
- **Google Scholar:** <https://scholar.google.com/citations?user=6bBCUW4AAAAJ&hl=en>
- **ORCID:** <https://orcid.org/0000-0002-1440-6875>

### **Academic/Research Experience**

- Scientist - III, National Institute of Biologicals (NIB), Noida, since Oct. 2015 to till date.
- Jr. Scientist - III, National Institute of Biologicals (NIB), Noida, since March, 2010 to Oct. 2015.
- Executive (Quality Control), Torrent Pharmaceuticals Ltd. (India) from 2008 to 2010.
- Research publications, N=33 (28 research articles, 01 book chapter, 04 abstracts published).
- Conferences (Total=25): Organized, N=1; Paper/Oral presentation, N=8; Poster presentation, N=3, Attended, N=13.
- Guide in more than 50 M.Sc. / M. Tech (Biotech) / B. Tech (Biotech) students in their dissertation research work.

### **Awards / Recognitions**

- Notified by Ministry of Health & Family Welfare, Govt. of India as 'Government Analyst' for Therapeutic Monoclonal antibodies (Rituximab, Trastuzumab, Bevacizumab, Adalimumab) vide Gazette notification no. 4271(E) dt. 26.11.2019.
- Expert Member in the Scientific Committees (International/National):

1. Member of WHO Scientific Development Committee for Preferred Product Characteristics and Clinical Development of Malaria Monoclonal antibodies for malaria prevention.
2. Member of the Implementation Committee establishing a Virology BSL2+ at CSIR-IMTECH, Chandigarh.
3. Member of 'Bioassay Expert Committee' at Indian Pharmacopoeia Commission (IPC), Ghaziabad for establishment of *in-vitro* cell culture lab in "Advanced Level Research Centre".
4. Member of Committee on Conformity Assessment (CASCO) / Committee on Reference Materials (REMCO) / National Mirror Committee (NMC), sub-committee-3, a technical Committee of Bureau of Indian Standards on "Laboratory and REMCO".
5. Inspected (N=12) manufacturing sites in India as Subject Expert in various Regulatory Inspections with Central Drugs Standard Control Organization (CDSCO), New Delhi.

#### **Research Projects**

1. Development of HER2 expression based *in-vitro* bioassay for biological activity of anti-HER2 therapeutic monoclonal antibodies. (ICMR) (Co-PI) (Ongoing).
2. Analytical profiling of Anti-HER2 monoclonal antibody biosimilars marketed in India. (NIB-Intramural) (Ongoing).
3. Rapid microbiological Method for Sterility testing of Biotherapeutics. (Intramural) (Ongoing).
4. Alternative economic bioassay for evaluation of biological activity of Vedolizumab to FACS based assay. (NIB-Intramural) (Completed).
5. Analytical and functional characterization of Anti-CD20 monoclonal antibody biosimilars marketed in India. (NIB-Intramural) (Completed).
6. Analytical profiling of Bevacizumab biosimilars marketed in India. (NIB-Intramural) (Completed).

#### **Major Publications**

1. **Subhash Chand**, Vikrant Mehta, Ratnesh K Sharma, Anupkumar R Anvikar, Harish Chander. Cancer informatics analysis indicates high CHAC2 associated with unfavorable prognosis in breast cancer. *Frontiers in Oncology* (2022). 9;12:1058931. (Impact factor 5.7)
2. Swati Shalini, Anu Sharma, Nripendra Nath Mishra, Ratnesh Kumar Sharma, Harish Chander, Anupkumar R Anvikar, **Subhash Chand\***. Cost effective and reliable cell based ELISA as an alternative method of flow cytometry for assessment of binding activity of Vedolizumab. *Heliyon* (2023). 9(2); e13570. (Impact factor 3.7).  
\*Corresponding Author.

3. Kanti Nandan Mihooliya, Jitender Nandal, Nidhi Kalidas, **Subhash Chand**, Dipesh Kumar Verma, Mani Shankar Bhattaharyya, Debendra K Sahoo. Assessment of structural behaviour of new L-asparaginase and SAXS data-based evidence for catalytic activity in its monomeric form. *bioRxiv* (2023). 2023.01. 01.522448.
4. Kumar Anand, Vijay Kumar, Indu Bhushan Prasher, Megha Sethi, Harsh Raj, Himanshu Ranjan, **Subhash Chand**, Gaurav Kumar Pandey. Bioactive molecules from fungal endophytes and their applications in pharmaceutical industries: challenges and future scope. *J Basic Microbiol.* (2023). doi: 10.1002/jobm.202200696. (Impact factor 2.6)
5. Nripendra Nath Mishra, Anu Sharma, Swati Shalini, Sonia Sharma, Paras Jain, Ratnesh K. Sharma, Harish Chander, J.P. Prasad, Anupkumar R. Anvikar, and **Subhash Chand\***. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy* (2022). 41(5): 260-274. (Impact factor 3.26). \*Corresponding Author.
6. **Subhash Chand**, K.N. Mihooliya, D.K. Sahoo, J.P. Prasad, Girish Sharma. L-asparaginase from *Bacillus flexus* SS: Isolation, screening, production process optimization, purification, and anticancer activity. *Applied Biochemistry and Microbiology* (2022). 58(4): 416-427 (Impact factor 1.2)
7. Anu Prakash, Nripendra N. Mishra, Utpreksha Vaish, Sonia Sharma, Apoorva Anand, Richi V. Mahajan, J.P. Prasad, **Subhash Chand\***. Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study. *3 Biotech* (2020). 10:516. (Impact factor 3.2). \*Corresponding Author.
8. **Subhash Chand**, Utpreksha Vaish, Anu Sharma, Nripendra N. Mishra, J.P. Prasad, Richi V. Mahajan. A reliable assay for ensuring the biological activity of Anti-T lymphocyte immunoglobulin as an alternate to compendial flow cytometer method. *Biologicals* (2020). Vol 65: 33-38. (Impact factor 1.8)
9. **Subhash Chand**, Richi V. Mahajan, J.P. Prasad, D.K. Sahoo, K.N. Mihooliya, M.S. Dhar, Girish Sharma. A comprehensive review on microbial L-asparaginase: Bioprocessing, characterization, and industrial applications. *Biotechnology and Applied Biochemistry* (2020). Vol. 67 (4): 619-647. (Impact factor 2.7)
10. Jaipal Meena , Shivani sood, Neha rani, Roshita Bisht, Manjula Kiran, Reba Chhabra, Surinder Singh, **Subhash Chand\***. Estimation of potency of Hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control laboratory. *Biologicals* (2019). Vol 59, 72-73. (Impact factor 1.8). \*Corresponding Author.
11. **Subhash Chand**, Birendra Kumar, Vivek M. Prathap, Surinder Singh, Richi V. Mahajan. Quality assurance of Rituximab (anti-CD 20) antibodies by potency testing: Determining the System Suitability Criteria and Sample Acceptance Criteria. *Current Science* (2018). Vol.114 (12), 2513-2518. (Impact factor 1.1).